1556 related articles for article (PubMed ID: 17678953)
21. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].
Hattori N
Rinsho Shinkeigaku; 2004; 44(4-5):241-62. PubMed ID: 15287506
[TBL] [Abstract][Full Text] [Related]
22. Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage.
Lipton SA
Surv Ophthalmol; 2003 Apr; 48 Suppl 1():S38-46. PubMed ID: 12852433
[TBL] [Abstract][Full Text] [Related]
23. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
Tanović A; Alfaro V
Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
[TBL] [Abstract][Full Text] [Related]
24. Management of moderate to severe Alzheimer's disease: focus on memantine.
Dominguez E; Chin TY; Chen CP; Wu TY
Taiwan J Obstet Gynecol; 2011 Dec; 50(4):415-23. PubMed ID: 22212311
[TBL] [Abstract][Full Text] [Related]
25. Synapses, NMDA receptor activity and neuronal Aβ production in Alzheimer's disease.
Bordji K; Becerril-Ortega J; Buisson A
Rev Neurosci; 2011; 22(3):285-94. PubMed ID: 21568789
[TBL] [Abstract][Full Text] [Related]
26. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
Sas K; Robotka H; Toldi J; Vécsei L
J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
[TBL] [Abstract][Full Text] [Related]
27. Protein disulfide isomerase P5-immunopositive inclusions in patients with Alzheimer's disease.
Honjo Y; Horibe T; Torisawa A; Ito H; Nakanishi A; Mori H; Komiya T; Takahashi R; Kawakami K
J Alzheimers Dis; 2014; 38(3):601-9. PubMed ID: 24037032
[TBL] [Abstract][Full Text] [Related]
28. New targets for pharmacological intervention in the glutamatergic synapse.
Gardoni F; Di Luca M
Eur J Pharmacol; 2006 Sep; 545(1):2-10. PubMed ID: 16831414
[TBL] [Abstract][Full Text] [Related]
29. Redox regulation of mitochondrial fission, protein misfolding, synaptic damage, and neuronal cell death: potential implications for Alzheimer's and Parkinson's diseases.
Nakamura T; Lipton SA
Apoptosis; 2010 Nov; 15(11):1354-63. PubMed ID: 20177970
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of Neuronal Protection against Excitotoxicity, Endoplasmic Reticulum Stress, and Mitochondrial Dysfunction in Stroke and Neurodegenerative Diseases.
Prentice H; Modi JP; Wu JY
Oxid Med Cell Longev; 2015; 2015():964518. PubMed ID: 26576229
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo.
Parsons CG; Quack G; Bresink I; Baran L; Przegalinski E; Kostowski W; Krzascik P; Hartmann S; Danysz W
Neuropharmacology; 1995 Oct; 34(10):1239-58. PubMed ID: 8570022
[TBL] [Abstract][Full Text] [Related]
32. Accumulation of misfolded protein through nitrosative stress linked to neurodegenerative disorders.
Uehara T
Antioxid Redox Signal; 2007 May; 9(5):597-601. PubMed ID: 17465882
[TBL] [Abstract][Full Text] [Related]
33. Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat.
Rosi S; Vazdarjanova A; Ramirez-Amaya V; Worley PF; Barnes CA; Wenk GL
Neuroscience; 2006 Nov; 142(4):1303-15. PubMed ID: 16989956
[TBL] [Abstract][Full Text] [Related]
34. Similarity of neuronal cell injury and death in AIDS dementia and focal cerebral ischemia: potential treatment with NMDA open-channel blockers and nitric oxide-related species.
Lipton SA
Brain Pathol; 1996 Oct; 6(4):507-17. PubMed ID: 8944320
[TBL] [Abstract][Full Text] [Related]
35. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity.
Volbracht C; van Beek J; Zhu C; Blomgren K; Leist M
Eur J Neurosci; 2006 May; 23(10):2611-22. PubMed ID: 16817864
[TBL] [Abstract][Full Text] [Related]
36. Protein disulfide isomerase-immunopositive inclusions in patients with Alzheimer disease.
Honjo Y; Ito H; Horibe T; Takahashi R; Kawakami K
Brain Res; 2010 Aug; 1349():90-6. PubMed ID: 20550946
[TBL] [Abstract][Full Text] [Related]
37. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
Wenk GL
J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
[TBL] [Abstract][Full Text] [Related]
38. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.
Kornhuber J; Weller M
Biol Psychiatry; 1997 Jan; 41(2):135-44. PubMed ID: 9018383
[TBL] [Abstract][Full Text] [Related]
39. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity.
Chen HS; Pellegrini JW; Aggarwal SK; Lei SZ; Warach S; Jensen FE; Lipton SA
J Neurosci; 1992 Nov; 12(11):4427-36. PubMed ID: 1432103
[TBL] [Abstract][Full Text] [Related]
40. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.
Parsons CG; Stöffler A; Danysz W
Neuropharmacology; 2007 Nov; 53(6):699-723. PubMed ID: 17904591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
